

Pan-Canadian Pharmaceutical Alliance: Negotiations being considered by each Province/Territory

As of April 30, 2019

The pCPA has recommended that negotiations for the following 13 brand name drug products be considered by each Province/Territory individually:

Drug Product Brand Name (Generic Name)	Indication/Use
Actemra (tocilizumab)	Used to treat polyarticular juvenile idiopathic arthritis (pJIA)
Botox (onabotulinumtoxinA)	Used to treat chronic migraine
Botox (onabotulinumtoxinA)	Used to treat overactive bladder
Fycompa (perampanel)	Used to treat seizures
Genotropin (somatropin)	Used to treat growth hormone deficiency and Turner's syndrome
Humalog 200 units/ml (insulin lispro)	Used to treat Type 1 and 2 diabetes
Humira (adalimumab)	Used to treat polyarticular juvenile idiopathic arthritis
Jentaduetto (linagliptin/metformin)	Used to treat Type 2 diabetes
Komboglyze (saxagliptin/metformin)	Used to treat Type 2 diabetes
Latuda (lurasidone)	Used to treat schizophrenia
Lodalis powder for oral solution (colesevelam)	Used to treat hypercholesterolemia (line extension)
Lucentis (ranibizumab)	Used to treat choroidal neovascularization secondary to pathologic myopia
Trisenox (arsenic trioxide)	Used to treat acute promyelocytic leukemia

* No new drug products since last update of March 31, 2019.

Factors considered by provinces and territories in pursuing individual drug negotiations include Canadian Drug Expert Committee (CDEC) or pan-Canadian Oncology Drug Review Expert Review Committee (pERC) recommendations, listing status of alternatives and the overall value of joint negotiations for the particular product.